Further immunological studies and a role of RNF43 mutation and translocations/overexpression of R-spondin in the progression of colon cancer is planned, to explore valid biomarkers that predict clinical efficacy of immune therapy. This evidence concerns the gene RNF43 and malignant colon neoplasm.